The IMID drug discovery company. Committed to improving the lives of patients with immune-mediated inflammatory diseases.
Barcelona and San Francisco CA
Joined December 2019
- Tweets50
- Following65
- Followers105
- Likes35
What's the future of #autoimmunedisease treatment? Our partnership with @FormationBio aims to answer that question! Check out our latest video featuring Fred Craves discussing the collaboration & its potential impact on #autoimmunedisease treatment #drugdiscovery #PrecisionMedicine #Biotech
@IMIDomics discovered the initial science, and now
@formationbio is taking it forward to clinical development. Today we announced our license of IMIDomics' first-in-class, Phase-1 ready anti-CD226 antibody targeting Ulcerative Colitis. Go behind the scenes with both teams here.
Exciting news! We have partnered with @FormationBio to advance our first-in-class anti-CD226 monoclonal antibody program for #autoimmunediseases. This collaboration marks a key step in our mission to bring innovative treatments to patients currently underserved by existing IMID therapies. Learn more: prnewswire.com/news-releases… #drugdiscovery #PrecisionMedicine #Biotech
Thrilled to be recognized in @UCB_news’ 2024 Annual Report! Our collaboration is driving innovation in IMID research, developing targeted therapies for immune-mediated inflammatory diseases. #Biotech #IMID #Collaboration #UCB #PrecisionMedicine
We are thrilled to announce that respected Matthias Evers, Ph. D., will join the IMIDomics Board of Directors effective October 1, 2024. Dr. Evers' significant expertise and insights will be critical as we advance our mission of delivering breakthrough medicines for IMIDs.
We are honored and excited to announce a strategic equity investment from @UCB_News Together, we look forward to advancing novel solutions that address the unmet needs of patients suffering from #IMIDs.
Read more here: ucb.com/stories-media/Press-…
Pleased to announce a strategic investment in IMIDomics.🎉 Their innovative approach in developing novel medicines aligns with our mission to improve patient lives. #UCB #IMIDomics #Innovation.
IMIDomics retweeted
Pleased to announce a strategic investment in IMIDomics.🎉 Their innovative approach in developing novel medicines aligns with our mission to improve patient lives. #UCB #IMIDomics #Innovation.
“Today, we announced the expansion of our strategic collaboration with @bmsnews to accelerate research and development aimed at understanding and uncovering mechanisms driving Sjögren's disease and atopic dermatitis.”
businesswire.com/news/home/2…
Thrilled to announce Dr. Eric Perakslis as our new Senior VP & CTO, bringing stellar expertise in pharma R&D. Welcoming Dr. Ramon Felciano as a strategic advisor in biomedical AI and data science. Exciting times ahead shaping the future of IMIDomics!
businesswire.com/news/home/2…
We are excited to announce a license and collaboration agreement with @UniBarcelona (UB) to advance treatments of #IMIDs, developing new therapeutic approaches for two new drug targets IMB-1003 and IMB-1004.
businesswire.com/news/home/2…
Congratulations to Dr. Sara Marsal on receiving the Trifermed Award for Social Impact in Healthcare!
awards.trifermed.com/?_gl=1%…
Dr. Marsal's remarkable dedication to the field of rheumatology and her outstanding contributions to the understanding and treatment of IMIDs.
Today, we announced a strategic agreement with @WuXiBiologics to accelerate the development and manufacturing of IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target for treating #IMIDs.
Read more: businesswire.com/news/home/2…
We are excited to announce our multi-program collaboration with @TwistBioscience to conduct antibody discovery activities against targets for patients with #IMIDs
Read more: businesswire.com/news/home/2…
IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases
businesswire.com/news/home/2…
We’re thrilled to announce the creation of our Immunology Advisory Board. The luminaries will support us refine our Precision Discovery Engine, and moving forward with identifying and pursuing targets for potential new treatments#IMIDs.
businesswire.com/news/home/2…
IMIDomics retweeted
📰 Las #biotech del @PCB_UB captan 39 M€, las más destacadas:
👉 @_inBrain 14,3 M€
👉 @IMIDomics 16,5 M€
✅ El vivero de la @UniBarcelona acoge +130 entidades y 3000 profesionales.
Según el #BioRegionReport 2021, la financiación en Cataluña fue de 238 M€.
@exp_catalunya
@IMIDomics is proud to have contributed to the early identification of #abatacept as a candidate immune modulator to reduce mortality in severe #COVID19 xitter.cf/ToniJuliaC/status/1538…
NIH ACTIV-1 clinical trial on immunomodulators for severe #COVID19 is out! In line with our prediction, #abatacept reduces the risk of death
nih.gov/news-events/news-rel…
Proud to receive this recognition from the CataloniaBio & HealthTech. It reflects our continuous commitment to IMID patients.
en.vhir.org/portal1/news-det…
IMIDomics retweeted
. @IMIDomics, spin-off de #VallHebron centrada en el descubrimiento y desarrollo de nuevas dianas y medicamentos para el tratamiento de enfermedades inflamatorias inmunomediadas (IMID), ha recibido una nueva inversión de capital de @Evotec.
Lee más: bit.ly/3pLrNHj
We are thrilled to announce that @Evotec has made a strategic investment in IMIDomics that reflects our shared goal of leveraging data to discover and develop meaningful treatments to improve the health and quality of life of IMID patients.
businesswire.com/news/home/2…
We’re thrilled to announce the creation of our Scientific Advisory Board and Business Advisory Board. The esteemed members will support us as we continue our precision discovery efforts to identify new therapies for #IMIDs. More Information: businesswire.com/news/home/2…
